Dernièrement…

📣 Communiqué de presse : https://bit.ly/3yqFJbG
#Amoéba $ALMIB annonce un report de la conclusion d’évaluation du dossier substance active #biocide. L’Autorité maltaise s’est engagé à finaliser le rapport au cours du 4ème trimestre 2021.

📣 #Amoéba $ALMIB met à disposition le Procès Verbal de son Assemblée Générale Ordinaire et Extraordinaire du 24 juin 2021.
Disponible ici : https://bit.ly/3AqWW6t

🇫🇷 @BpifranceHub et @FRdigitale publient le 1er mapping des startups à #Impact.
💚 #Amoéba est fier d’être référencé dans la catégorie #Environnement.
Découvrez les 727 startups qui font bouger les lignes
FD 👉https://bit.ly/fd-impact
BPI 👉https://bit.ly/bpi-impact

📣 Communiqué de Presse : https://bit.ly/3gUnTaO
#Amoéba annonce la nomination de M.Philippe Dujardin en qualité d’administrateur indépendant du Conseil d’Administration, en remplacement de M.Pascal Reber pour la durée du mandat restant à courir de son prédécesseur $ALMIB

Amoéba Company

Management Committee

Fabrice PLASSON, CEO and Chairman

Fabrice PLASSON has more than 20 years of experience in the fields of life sciences and biotechnologies. Before creating Amoéba, he was Managing Director and founder of the French division of DiscoveRx, where he was responsible for sales in Southern Europe. His experience at DiscoveRx gave him a global vision of the sale of products and services to research centers working on the discovery of new drugs. Fabrice PLASSON previously worked at Whatman Ltd. in France where he was responsible for leading the international distributor network. In this position, he helped Whatman Ltd. to successfully establish itself in the French genetic fingerprinting market. Previously, Fabrice PLASSON had developed Oxoid’s sales and had been called as a consultant on legionella risk by hospitals and companies. He holds a double master’s degree in Biology and Marketing from the Joseph Fourier University in Grenoble and an Executive MBA (Executive Masters of Business Administration) from EM-Lyon.

Valérie FILIATRE, Deputy General Manager

Valérie FILIATRE has acquired more than 30 years of experience in administrative and financial management of European and American listed companies. Prior to joining Amoéba, Valérie held the position of Chief Financial Officer Europe at ABnote Corporation, one of the world leaders in the security of financial, government, transportation and educational institutions documents. In this position, Valérie was responsible for the consolidation of financial reports for France, Czech Republic, Slovakia and the UK subsidiaries, while contributing to the restructuring of the latter entities. Valérie is a graduate of EM Lyon, where she specialized in finance and accounting.

Jean-Luc SOUCHE, Business Development Biocontrol

Jean-Luc SOUCHE, 36 years of experience in life sciences, is a specialist in plant protection. He has held various technical and marketing positions, in France and abroad, at Rhône-Poulenc Agrochimie.  After an experience in biotechnology at Metabolic Explorer, he became in 2013 the CEO of Agrauxine, a French start-up specialized in biocontrol, and then took over the business development of the company after its acquisition by the Lesaffre group. He contributed to the international development of the range of biofungicides for vineyards, market gardening and post-harvest treatment of fruits.

Jean-Luc is an agricultural engineer graduated from the Institut National Agronomique Paris Grignon (now AgroparisTech) and holds an executive MBA from HEC.

Sandrine DEMANECHE, Scientific Director

Sandrine DEMANECHE, Doctor of Science, has more than 20 years of experience in research and development in the field of environmental microbiology. She has published 25 articles in peer-reviewed scientific papers. Before joining Amoéba, she was responsible for a sequencing platform and the realization of research projects in microbial ecology in an engineering school (Ecole Centrale de Lyon). Sandrine DEMANECHE is a graduate of Claude Bernard University in Lyon.

Jean-Baptiste EBERST, Regulatory Affairs Director

Jean-Baptiste EBERST has more than 10 years of experience in Regulatory Affairs in various regulated fields, including health and pest control products. Before joining Amoéba in 2015, he worked in the pharmaceutical (Sanofi Pasteur, Merck Serono) and medical device (Integra LifeSciences) industries, where he was in charge of the regulatory management of product portfolios in various regions (USA, Europe, Canada, Middle East). He has a strong knowledge in regulatory product approval and regulatory compliance assurance. Jean-Baptiste is a pharmacist, graduated from the University of Strasbourg.

 

Our story

The patent discovery

Amoéba is an innovative company, created in July 2010 by Fabrice PLASSON.

When the company was founded, its initial objective was to develop a patent from the University of Lyon. This patent is based on a single-celled microscopic organism isolated from a natural environment, the amoeba Willaertia magna C2c Maky, which is able to fight against the proliferation of legionella.

Amoéba then began the development of a new biological biocide for the industrial control of legionella, free amoebae and biofilm.

A successful IPO

In July 2015, Amoéba was listed on the regulated market of Euronext, Paris.

This successful IPO allowed the company to raise €13.2M.

Thanks to this, Amoéba has been able to develop its scientific, industrial and commercial expertise around the amoeba. We are now able to offer technological solutions and products in a wide range of applications.

A diversification of the offer

Amoéba has developed two technologies.

The first one is used for the treatment of water, surfaces and chronic wounds and uses the natural biocidal capacity of the living amoeba Willaertia magna C2c Maky.

The second technology is dedicated to agriculture and more precisely to biocontrol for the treatment of phytopathogenic microorganisms using the lysed (non-living) form of this same amoeba.

Our mission

At the crossroads of environmental protection and public health issues, we are developing a three-fold scientific, industrial and commercial expertise. The company is developing around multiple applications using the amoeba Willaertia magna C2c Maky in the prevention of microbiological risk for water treatment, human wounds and plant protection.

Our commitment

With the growing awareness of the fragility or scarcity of key natural resources such as water, air and food, Amoéba wants to be a major player in the biological revolution in the treatment of these crucial resources, with a global and integrated vision of environmental and health issues. By offering world-class natural solutions that are alternative or complementary to chemical treatments, more respectful of ecosystems, technologically efficient and economically viable, we want to have a concrete impact on the new environmental balances and on tomorrow’s society.

 

Our values

Make it bold.

We develop disruptive technologies to bring out new alternative solutions, so taking risks is an integral part of our project.

Make it simple.

We always aim for scientific and technological excellence, and we emphasize simplicity and pragmatism in our relationships and operating processes.

Make it happen.

Saying what we are going to do and doing what we said we would do to make our projects a reality, deliver the expected results and be trustworthy over the long term.

Make it fun.

With an ambitious and demanding entrepreneurial project, friendliness, solidarity and efficiency go hand in hand. Having fun at work is a state of mind that everyone must maintain.

Our vision

By 2024, we want to have demonstrated our usefulness and influence by being commercially present in three areas of application: water treatment, agriculture and human health. In this way, we hope to have paved the way for further research and development of alternatives to chemical treatments of our key resources.

Want to join the Amoeba adventure ?

To make our common project grow, join us by sending us your application !

Apply